Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...

Stifel analysts maintained a Buy rating and a $92.00 price target for Globus Medical (NYSE:GMED) stock following the company's announcement of acquiring Nevro Corp . (NYSE:NVRO) for an equity value of ...

In a report released today, David Saxon from Needham maintained a Hold rating on Globus Medical (GMED – Research Report). The company’s shares ...

Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...

Globus Medical is acquiring Nevro Corp, a spinal cord stimulator company, according to a Feb. 6 news release. Globus Medical's transaction will include all shares of Nevro, which are valued at about ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per ...

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

As of Feb. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as ...

KBC Group NV grew its position in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 1.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities ...